TORNTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Torrent Pharmaceuticals reported strong FY26 standalone results with revenue of Rs 10,498 crores (up 10.7% YoY) and net profit of Rs 2,192 crores (up 16.1% YoY). EPS improved to Rs 64.75 from Rs 55.79. The Board recommended a final dividend of Rs 9 per share (180%) following an earlier interim dividend of Rs 29 per share, bringing total FY26 dividend to Rs 38 per share. Record date is May 29, 2026 with payment around June 25, 2026. The company also got shareholder approval for raising up to Rs 5,000 crores via QIP. Notably, the company completed its major acquisition of J.B. Chemicals & Pharmaceuticals (JB Pharma) for approximately Rs 12,537 crores, which has significantly increased its debt equity ratio to 1.68 (from 0.34).
The stock is likely to react positively to strong earnings growth and consistent dividend payouts, though elevated debt levels from the JB Pharma acquisition may concern some investors. The QIP approval signals potential dilution ahead.